Drug intelligence / Profile preview

NTQ5082

Development stage: Phase 3
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

NTQ5082 is a small molecule inhibitor of complement factor B (CFB), developed by Nanjing Chia Tai Tianqing Pharmaceutical. It is being investigated primarily for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The drug acts by inhibiting CFB, a key component in the alternative pathway of the complement system, which plays a role in hemolysis seen in PNH. As of early 2025, NTQ5082 has reached Phase 2 clinical trials for PNH and has also been studied in Phase 1 trials to assess safety and pharmacokinetics in healthy volunteers[1][2][4][5].

Targets

CFB (Complement Factor B)

Beyond the preview

Go deeper on NTQ5082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTQ5082.

Explore the full profile